Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936260 | 0.88 | PTGS2 (0.43) | L3MBTL1LMNAPKMPTGS2ALDH1A1 | |
| SCHEMBL16936411 | 0.87 | TAS2R14 (0.40) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16936385 | 0.85 | ERCC5 (0.39) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16937023 | 0.84 | TAS2R14 (0.38) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16936270 | 0.83 | L3MBTL1 (0.37) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16936627 | 0.83 | UCHL1 (0.43) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL20315214 | 0.83 | LMNA (0.43) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16936383 | 0.82 | SMN1; SMN2 (0.37) | L3MBTL1TAS2R14LMNASMN1; SMN2APLNR | |
| SCHEMBL16936721 | 0.81 | RET (0.41) | LMNASMN1; SMN2 | |
| SCHEMBL30489532 | 0.81 | RET (0.41) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096754-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | L3MBTL1 1082/4885TAS2R14 4657/4885LMNA 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.